Accéder au contenu
Merck

The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.

Nature cell biology (2016-05-24)
Veronica Torrano, Lorea Valcarcel-Jimenez, Ana Rosa Cortazar, Xiaojing Liu, Jelena Urosevic, Mireia Castillo-Martin, Sonia Fernández-Ruiz, Giampaolo Morciano, Alfredo Caro-Maldonado, Marc Guiu, Patricia Zúñiga-García, Mariona Graupera, Anna Bellmunt, Pahini Pandya, Mar Lorente, Natalia Martín-Martín, James David Sutherland, Pilar Sanchez-Mosquera, Laura Bozal-Basterra, Amaia Zabala-Letona, Amaia Arruabarrena-Aristorena, Antonio Berenguer, Nieves Embade, Aitziber Ugalde-Olano, Isabel Lacasa-Viscasillas, Ana Loizaga-Iriarte, Miguel Unda-Urzaiz, Nikolaus Schultz, Ana Maria Aransay, Victoria Sanz-Moreno, Rosa Barrio, Guillermo Velasco, Paolo Pinton, Carlos Cordon-Cardo, Jason W Locasale, Roger R Gomis, Arkaitz Carracedo
RÉSUMÉ

Cellular transformation and cancer progression is accompanied by changes in the metabolic landscape. Master co-regulators of metabolism orchestrate the modulation of multiple metabolic pathways through transcriptional programs, and hence constitute a probabilistically parsimonious mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) suppresses prostate cancer progression and metastasis. A metabolic co-regulator data mining analysis unveiled that PGC1α is downregulated in prostate cancer and associated with disease progression. Using genetically engineered mouse models and xenografts, we demonstrated that PGC1α opposes prostate cancer progression and metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that PGC1α activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis suppression. Importantly, a signature based on the PGC1α-ERRα pathway exhibited prognostic potential in prostate cancer, thus uncovering the relevance of monitoring and manipulating this pathway for prostate cancer stratification and treatment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps monoclonal anti-β-actine antibody produced in mouse, clone AC-74, ascites fluid
Sigma-Aldrich
MISSION® esiRNA, targeting human PPARGC1A (2)
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Ppargc1a